This study is looking at whether the medication tesamorelin, when combined with exercise, can improve physical function and muscle health in adults with HIV. Tesamorelin is already approved to treat abdominal fat in people with HIV. We are enrolling 100 participants, aged 50-80, who have HIV, are on stable treatment, and lead a sedentary lifestyle. The main goal is to see if participants can stand up from a chair faster after 24 weeks. The study status is currently unclear, but we are looking for people who meet these criteria.

Study design

This interventional study plans to enroll 100 participants. It will compare tesamorelin plus exercise to a placebo plus exercise.

What's involved

Participants will receive daily subcutaneous injections of either tesamorelin or a placebo, and participate in a home-based, semi-supervised exercise program. The primary endpoint is measured at 24 weeks.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured at 24 weeks after starting the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.